CIDeRplusGeneral Information:
| Id: | 3,562 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Homo sapiens | |
| article | |
| Reference: | Bao Y et al.(2009) Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers J. Proteome Res. 8: 1623-1630 [PMID: 19714868] |
Interaction Information:
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33188 |
disease increases_quantity of drug/chemical compound |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33189 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33190 |
disease increases_quantity of drug/chemical compound |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33191 |
disease increases_quantity of drug/chemical compound |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33192 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33193 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33194 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33195 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33196 |
disease increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33197 |
disease decreases_quantity of drug/chemical compound |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33198 |
disease decreases_quantity of drug/chemical compound |
| Comment | As compared to healthy controls, the altered serum metabolites in diabetic subjects, include the significantly increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. These findings suggest a hypercatabolic state in T2DM patients. |
|
Formal Description Interaction-ID: 33199 |
disease decreases_quantity of drug/chemical compound |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33200 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33201 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone or Maltose |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33202 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone or Butanoic acid |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33203 |
drug/chemical compound increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33204 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone or Palmitic acid |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33205 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone or Oleic acid |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33206 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33207 |
drug/chemical compound increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33208 |
|
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Multivariate statistics indicated the rosiglitazone-mediated normalization of 8-10 key metabolites at 24 and 48 weeks, which were differentially expressed in diabetic subjects, involving glutamate, maltose, butanoate, glucuronolactone, C16:0, C18:1. In repaglinide and metformin groups, only glutamate and lysine (in repaglinide group at 48 week only) were brought to the normal level. |
|
Formal Description Interaction-ID: 33209 |
|
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | All of the three treatments were able to down-regulate the high level of glutamate to a lower level in serum, suggesting a possible effect on prevention and amelioration of diabetic complications in T2DM patients, since it has been reported that a high level of serum glutamate is involved in immunodeficiency, amyotrophic lateral sclerosis, and neurological complications. |
|
Formal Description Interaction-ID: 33210 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone |
| Comment | All of the three treatments were able to down-regulate the high level of glutamate to a lower level in serum, suggesting a possible effect on prevention and amelioration of diabetic complications in T2DM patients, since it has been reported that a high level of serum glutamate is involved in immunodeficiency, amyotrophic lateral sclerosis, and neurological complications. |
|
Formal Description Interaction-ID: 33211 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide |
| Comment | All of the three treatments were able to down-regulate the high level of glutamate to a lower level in serum, suggesting a possible effect on prevention and amelioration of diabetic complications in T2DM patients, since it has been reported that a high level of serum glutamate is involved in immunodeficiency, amyotrophic lateral sclerosis, and neurological complications. |
|
Formal Description Interaction-ID: 33212 |
|
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33213 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone or Fructose |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33214 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide or Fructose |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33215 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33216 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33217 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33218 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33219 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone or Maltose |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33220 |
drug/chemical compound affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide or Maltose |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33221 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Repaglinide |
| Comment | Concentrations of several carbohydrates including fructose, alpha-galactose, mannose and maltose were significantly altered, in addition to glucose levels, by rosiglitazone and repaglinide treatments. |
|
Formal Description Interaction-ID: 33222 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone |
| Comment | Alpha-glycerophosphorate, an important participant of alpha-glycerophosphoric acid shuttle system, was increased by rosiglitazone. |
|
Formal Description Interaction-ID: 33223 |
drug/chemical compound increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Rosiglitazone |
| Comment | Alpha-glycerophosphorate, an important participant of alpha-glycerophosphoric acid shuttle system, was increased by rosiglitazone. |
|
Formal Description Interaction-ID: 33224 |
|